(Q44551809)

English

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

scientific article published in December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Richard A. Larson

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hagop Kantarjian

13

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

8

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Srdan Verstovsek

7

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jorge Eduardo Cortes

6

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

11

object named as

Maher Albitar

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Francis J Giles

1

object named as

Francis J Giles

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

9

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

object named as

Gail J Roboz

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Lawrence Eric Feldman

2

object named as

Eric J Feldman

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Susan M O'Brien

12

object named as

Susan M O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Steven W Mamus

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Miloslav Beran

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1091-1096

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Troxacitabine-based therapy of refractory leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Transfer of the cytidine deaminase cDNA into hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel clinical strategies for the treatment of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Troxacitabine activity in extramedullary myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900094-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0145-2126(03)00094-8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44551809&oldid=2027698251"